Ametek (AME) to pay $0.14 on Mar 29, 2019; Alpine Immune Sciences (ALPN) Shorts Lowered By 35.96%

AMETEK, Inc. (NYSE:AME) Logo

Ametek Inc (NYSE:AME) is expected to pay $0.14 on Mar 29, 2019. (NYSE:AME) shareholders before Mar 14, 2019 will receive the $0.14 dividend. Ametek Inc’s current price of $78.77 translates into 0.18% yield. Ametek Inc’s dividend has Mar 15, 2019 as record date. Feb 13, 2019 is the announcement. The stock increased 1.85% or $1.43 during the last trading session, reaching $78.77. About 2.60M shares traded or 72.00% up from the average. AMETEK, Inc. (NYSE:AME) has declined 0.98% since February 14, 2018 and is downtrending. It has underperformed by 0.98% the S&P500. Some Historical AME News: 09/05/2018 – Matthew J. Conti Elected Vice President, Human Re; 02/05/2018 – AMETEK RAISES 2018 GUIDANCE; 09/04/2018 – AMETEK Prestolite Power Launches AMETEK Insight, a Cloud-Based Information Tool; 02/05/2018 – Ametek Sees 2018 EPS $3.06-EPS $3.12; 26/04/2018 – Ametek Presenting at Wells Fargo Industrials Conference May 8; 02/05/2018 – AMETEK 1Q EPS 78C, EST. 72C; 13/03/2018 AMETEK INC AME.N : COWEN AND COMPANY RAISES TARGET PRICE TO $83 FROM $80; RATING OUTPERFORM; 02/05/2018 – AMETEK BUYS SOUNDCOM SYSTEMS; 29/05/2018 – P&M Corporate Finance Announces the Sale of SoundCom Corp to AMETEK, Inc; 02/05/2018 – Ametek Sees 2Q EPS 76c-EPS 78c

Alpine Immune Sciences Inc (NASDAQ:ALPN) had a decrease of 35.96% in short interest. ALPN’s SI was 22,800 shares in February as released by FINRA. Its down 35.96% from 35,600 shares previously. With 8,500 avg volume, 3 days are for Alpine Immune Sciences Inc (NASDAQ:ALPN)’s short sellers to cover ALPN’s short positions. The stock increased 0.27% or $0.01 during the last trading session, reaching $5.66. About 12,543 shares traded. Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has declined 53.22% since February 14, 2018 and is downtrending. It has underperformed by 53.22% the S&P500. Some Historical ALPN News: 09/03/2018 – USGS: M 2.4 – 59km N of Sutton-Alpine, Alaska; 26/04/2018 – ALPINE ELECTRONICS 6816.T 2017/18 GROUP NET PROFIT 9.33 BLN YEN (+20.2 %), 2018/19 FORECAST PROFIT 10.00 BLN YEN (+7.2 %); 14/05/2018 – Apache Midstream and ARM Energy Holdings Announce Development of Salt Creek Midstream’s SCM Alpine, LLC; 07/03/2018 – An activist investor is balking at the plan; 11/03/2018 – USGS: M 3.1 – 81km E of Sutton-Alpine, Alaska; 04/04/2018 – USGS: M 1.2 – 5km NNE of Sutton-Alpine, Alaska; 14/05/2018 – Alpine Immune Sciences 1Q Loss/Shr 38c; 07/05/2018 – ABERDEEN STANDARD INVESTMENTS ANNOUNCES COMPLETION OF REORGANIZATION OF ASSETS FROM ALPINE WOODS CAPITAL INVESTORS, LLC INTO THE ABERDEEN FUNDS TRUST AND NEW INVESTMENT ADVISORY AGREEMENTS WITH; 10/03/2018 – Alpine skiing-Shiffrin wins slalom World Cup title; 13/04/2018 – USGS: M 2.0 – 60km E of Sutton-Alpine, Alaska

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. The company has market cap of $105.06 million. The Company’s lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. It currently has negative earnings. The firm has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein immunotherapies targeting the immune synapse to treat cancer.

More notable recent Alpine Immune Sciences, Inc. (NASDAQ:ALPN) news were published by: Seekingalpha.com which released: “Alpine Immune raises $25M via private placement – Seeking Alpha” on January 16, 2019, also Seekingalpha.com with their article: “Microcaps mostly among midday movers – Seeking Alpha” published on January 23, 2019, Seekingalpha.com published: “Alpine Immune Sciences: What The Q1 2018 Earnings Foretell? – Seeking Alpha” on June 07, 2018. More interesting news about Alpine Immune Sciences, Inc. (NASDAQ:ALPN) were released by: Seekingalpha.com and their article: “Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene – Seeking Alpha” published on October 11, 2018 as well as Seekingalpha.com‘s news article titled: “Rounds Report: Alpine Immune Sciences Broke The Trend In A Down Market – Seeking Alpha” with publication date: July 18, 2018.

Investors sentiment increased to 1.2 in 2018 Q3. Its up 0.04, from 1.16 in 2018Q2. It is positive, as 24 investors sold AMETEK, Inc. shares while 161 reduced holdings. 60 funds opened positions while 162 raised stakes. 188.53 million shares or 1.17% less from 190.75 million shares in 2018Q2 were reported. Walleye Trading Ltd Company reported 3,490 shares. Burney stated it has 0.08% of its portfolio in AMETEK, Inc. (NYSE:AME). 2.89 million are owned by Ameriprise Financial. Pension Serv reported 0.08% in AMETEK, Inc. (NYSE:AME). 185,667 are owned by Nomura Holdings. Smithfield Co owns 1,250 shares. Ascend Capital Ltd stated it has 1.32% of its portfolio in AMETEK, Inc. (NYSE:AME). Balyasny Asset Mgmt Limited Co reported 0.01% of its portfolio in AMETEK, Inc. (NYSE:AME). Alabama-based Fjarde Ap has invested 0.09% in AMETEK, Inc. (NYSE:AME). Cls Investments Limited Liability stated it has 0% of its portfolio in AMETEK, Inc. (NYSE:AME). Bnp Paribas Arbitrage Sa reported 0% in AMETEK, Inc. (NYSE:AME). Pub Employees Retirement Systems Of Ohio has 110,832 shares. 376,755 were reported by Credit Suisse Ag. Shufro Rose Ltd Co holds 0.03% or 4,624 shares in its portfolio. Moreover, Rampart Inv Mgmt Commerce Llc has 0% invested in AMETEK, Inc. (NYSE:AME) for 2,183 shares.

More news for AMETEK, Inc. (NYSE:AME) were recently published by: Benzinga.com, which released: “Thomas J. Matway Elected Vice President And General Manager, Specialty Metal Products Division – Benzinga” on February 13, 2019. Benzinga.com‘s article titled: “Earnings Scheduled For February 5, 2019 – Benzinga” and published on February 05, 2019 is yet another important article.

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices worldwide. The company has market cap of $18.28 billion. The Company’s Electronic Instruments Group segment offers advanced instruments for the process, power and industrial, and aerospace markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage markets; and instruments for the laboratory equipment, ultraprecision manufacturing, medical, and test and measurement markets. It has a 23.58 P/E ratio. This segment also provides aircraft and engine sensors, monitoring systems, power supplies, data acquisition units, and fuel and fluid measurement systems for the aerospace industry; and power quality monitoring and metering, uninterruptible power systems, programmable power equipment, electromagnetic compatibility test equipment, sensors for gas turbines, dashboard instruments for heavy trucks and other vehicles, and instrumentation and controls for the food and beverage industries.

AMETEK, Inc. (NYSE:AME) Institutional Positions Chart